ReviewMediators of inflammation2013
Visfatin/Nampt: an adipokine with cardiovascular impact.
Review in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 197 citations in OpenAlex.
- Trial
- Adiponectin in relation to exercise and physical performance in patients with type 2 diabetes and coronary artery disease.Adipocyte · 2021Trial
- Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study.Nutrients · 2017Trial
- Visfatin correlates with hot flashes in postmenopausal women with metabolic syndrome: effects of genistein.Endocrine · 2017Trial
- Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.Journal of bone and mineral metabolism · 2017Trial
- Biomarkers of Cardiovascular Stress: A Historical Review.Journal of cardiovascular development and disease · 2026Review
- Blood-based obesity biomarkers and their relevance for disease risk.Nature reviews. Endocrinology · 2026Review
- Profiling the secretome: maternal obesity impacts redox and adipogenic signaling during neonatal mesenchymal stem cell adipogenesis.Stem cells (Dayton, Ohio) · 2026Article
- Review
- Evaluation of Selected Serum Adipocytokines in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Immunomodulatory Second-Line Drugs.International journal of molecular sciences · 2025Article
- Adipokines in preeclampsia: disrupted signaling pathways and novel therapeutic strategies.European journal of medical research · 2025Review
- Role of Visfatin in Chronic Kidney Disease: Diagnostic Potential and Association with Hemodialysis.Reports of biochemistry & molecular biology · 2025Article
- Visfatin exerts an anti-proliferative and pro-apoptotic effect in the human placenta cells†.Biology of reproduction · 2025Article
- The eNAMPT-Integrin α5β1 Axis Mediates Neutrophil-Endothelial Cell Interactions Driving Inflammation in Ulcerative Colitis.Journal of inflammation research · 2025Article
- eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes.Diabetologia · 2024Article
- Expression of visfatin in gingival crevicular fluid and gingival tissues in different periodontal conditions: a cross-sectional study.BMC oral health · 2024Article
- Unlocking the Dietary Puzzle: How Macronutrient Intake Shapes the Relationship between Visfatin and Atherosclerosis in Type 2 Diabetes.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers.Cell communication and signaling : CCS · 2024Review
- The Role of Adipokines and Myokines in the Pathogenesis of Different Obesity Phenotypes-New Perspectives.Antioxidants (Basel, Switzerland) · 2023Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipose tissue is acknowledged as an endocrine organ that releases bioactive factors termed adipokines. Visfatin was initially identified as a novel adipokine with insulin-mimetic properties in mice. This adipokine was identical to two previously described molecules, namely, pre-B cell colony-enhancing factor (PBEF) and the enzyme nicotinamide phosphoribosyltransferase (Nampt). Enhanced circulating visfatin/Nampt levels have been reported in metabolic diseases, such as obesity and type 2 diabetes. Moreover, visfatin/Nampt circulating levels correlate with markers of systemic inflammation. In cardiovascular diseases, visfatin/Nampt was initially proposed as a clinical marker of atherosclerosis, endothelial dysfunction, and vascular damage, with a potential prognostic value. Nevertheless, beyond being a surrogate clinical marker, visfatin/Nampt is an active player promoting vascular inflammation, and atherosclerosis. Visfatin/Nampt effects on cytokine and chemokine secretion, macrophage survival, leukocyte recruitment by endothelial cells, vascular smooth muscle inflammation and plaque destabilization make of this adipokine an active factor in the development and progression of atherosclerosis. Further research is required to fully understand the mechanisms mediating the cellular actions of this adipokine and to better characterize the factors regulating visfatin/Nampt expression and release in all these pathologic scenarios. Only then, we will be able to conclude whether visfatin/Nampt is a therapeutical target in cardiometabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.